{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:39:40Z","timestamp":1770907180777,"version":"3.50.1"},"reference-count":53,"publisher":"Impact Journals, LLC","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2020,11,3]]},"DOI":"10.18632\/oncotarget.27775","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T16:39:35Z","timestamp":1604421575000},"page":"3984-3997","source":"Crossref","is-referenced-by-count":8,"title":["Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma"],"prefix":"10.18632","volume":"11","author":[{"given":"Rikio","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Center for Regenerative Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Center for Regenerative Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hibiki","family":"Akashi","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan"},{"name":"Center for Regenerative Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"36","author":"Anderson","year":"2011","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"37","author":"Anderson","year":"2009","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"11","author":"Gertz","year":"2008","journal-title":"Blood"},{"key":"4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/17474086.2019.1624158","article-title":"Novel targets for the treatment of relapsing multiple myeloma","volume":"1","author":"Malavasi","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2009.01.022","article-title":"Targeting the RAF-MEK-ERK pathway in cancer therapy","volume":"28","author":"Settleman","year":"2009","journal-title":"Cancer Lett"},{"key":"6","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/bcj.2013.1","article-title":"MEK inhibitors as a chemotherapeutic intervention in multiple myeloma","volume":"3","author":"Spencer","year":"2013","journal-title":"Blood Cancer J"},{"key":"7","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3324\/haematol.2018.211110","article-title":"Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma","volume":"10","author":"Kumar","year":"2019","journal-title":"Haematologica"},{"key":"8","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"2","author":"Fonseca","year":"2008","journal-title":"Leukemia"},{"key":"9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy","volume":"12","author":"Dorner","year":"2014","journal-title":"Blood"},{"key":"10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.18632\/oncoscience.479","article-title":"Localized RAS signaling drives cancer","volume":"6","author":"Johnson","year":"2019","journal-title":"Oncoscience"},{"key":"11","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3390\/cancers11091262","article-title":"BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors","volume":"1","author":"Pratilas","year":"2019","journal-title":"Cancers (Basel)"},{"key":"12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/neuonc\/now261","article-title":"A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas","volume":"1","author":"Kieran","year":"2017","journal-title":"Neuro Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1124\/jpet.118.253708","article-title":"Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases","volume":"36","author":"Elmquist","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-018-0856-3","article-title":"Critical role of FOXO3a in carcinogenesis","volume":"1","author":"Wang","year":"2018","journal-title":"Mol Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10495-014-1071-3","article-title":"FOXO3-mediated up-regulation of Bim contributes to rhein-induced cancer cell apoptosis","volume":"2","author":"Jiang","year":"2015","journal-title":"Apoptosis"},{"key":"16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.molmet.2015.01.003","article-title":"Clic4, a novel protein that sensitizes beta-cells to apoptosis","volume":"4","author":"Thorens","year":"2015","journal-title":"Mol Metab"},{"key":"17","doi-asserted-by":"publisher","first-page":"e1003532","DOI":"10.1371\/journal.pgen.1003532","article-title":"GLIS3, a susceptibility gene for type 1 and type 2 diabetes, modulates pancreatic beta cell apoptosis via regulation of a splice variant of the BH3-only protein Bim","volume":"9","author":"Eizirik","year":"2013","journal-title":"PLoS Genet"},{"key":"18","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"10","author":"Boise","year":"2006","journal-title":"Blood"},{"key":"19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"1","author":"Adjei","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"ra121","DOI":"10.1126\/scisignal.aaa1877","article-title":"Systematic identification of signaling pathways with potential to confer anticancer drug resistance","volume":"7","author":"Tetzlaff","year":"2014","journal-title":"Sci Signal"},{"key":"21","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"38","author":"Haanen","year":"2019","journal-title":"N Engl J Med"},{"key":"22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ctrv.2019.02.001","article-title":"Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma","volume":"7","author":"Xie","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"23","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.2147\/OTT.S182721","article-title":"Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma","volume":"1","author":"Mahmoud","year":"2018","journal-title":"Onco Targets Ther"},{"key":"24","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"2","author":"Fonseca","year":"2011","journal-title":"Leukemia"},{"key":"25","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1158\/0008-5472.CAN-13-3728","article-title":"Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers","volume":"7","author":"Engelman","year":"2014","journal-title":"Cancer Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/ijc.28550","article-title":"KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells","volume":"13","author":"Koizumi","year":"2014","journal-title":"Int J Cancer"},{"key":"27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1200\/JCO.2012.45.1492","article-title":"Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab","volume":"3","author":"Wiezorek","year":"2013","journal-title":"J Clin Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","article-title":"The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies","volume":"4","author":"Karachaliou","year":"2015","journal-title":"Nat Genet"},{"key":"29","doi-asserted-by":"publisher","first-page":"e0143847","DOI":"10.1371\/journal.pone.0143847","article-title":"Combination of a Selective HSP90alpha\/beta Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells","volume":"1","author":"Tai","year":"2015","journal-title":"PLoS One"},{"key":"30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nature14982","article-title":"RAF inhibitors that evade paradoxical MAPK pathway activation","volume":"52","author":"Cho","year":"2015","journal-title":"Nature"},{"key":"31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/1535-7163.MCT-15-0617","article-title":"A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation","volume":"1","author":"Kalkuhl","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"32","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.4049\/jimmunol.168.10.5024","article-title":"The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2","volume":"16","author":"Medema","year":"2002","journal-title":"J Immunol"},{"key":"33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1074\/jbc.M111.266940","article-title":"Cardiac hypertrophy is positively regulated by MicroRNA miR-23a","volume":"28","author":"Li","year":"2012","journal-title":"J Biol Chem"},{"key":"34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jsbmb.2016.09.009","article-title":"BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents","volume":"17","author":"Studzinski","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"key":"35","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study","volume":"1","author":"Corso","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"36","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","article-title":"How I treat first relapse of myeloma","volume":"13","author":"Attal","year":"2017","journal-title":"Blood"},{"key":"37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"7","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"38","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","article-title":"Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial","volume":"8","author":"Van Ness","year":"1996","journal-title":"Blood"},{"key":"39","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1038\/sj.onc.1207692","article-title":"MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol","volume":"2","author":"Craig","year":"2004","journal-title":"Oncogene"},{"key":"40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11912-019-0804-4","article-title":"Management of Newly Diagnosed Elderly Multiple Myeloma Patients","volume":"2","author":"Braunstein","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clml.2019.03.025","article-title":"Multiple Myeloma: Current Advances and Future Directions","volume":"1","author":"Huff","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"42","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.18632\/aging.101707","article-title":"How I treat elderly patients with plasma cell dyscrasias","volume":"1","author":"Dimopoulos","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/JBM.S102328","article-title":"New developments in the management of relapsed\/refractory multiple myeloma - the role of ixazomib","volume":"8","author":"Moreau","year":"2017","journal-title":"J Blood Med"},{"key":"44","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","article-title":"Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients","volume":"13","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"McCarthy","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"46","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"13","author":"Dunbar","year":"2017","journal-title":"Blood"},{"key":"47","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"9","author":"Greipp","year":"2002","journal-title":"Blood"},{"key":"48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"2","author":"Amiot","year":"2014","journal-title":"Leukemia"},{"key":"49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.semcancer.2017.09.007","article-title":"Epigenetics in multiple myeloma: From mechanisms to therapy","volume":"5","author":"Jernberg-Wiklund","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"50","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Anderson","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"51","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1182\/blood-2005-08-3434","article-title":"Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and inducesandcytotoxicity in human multiple myeloma cells","volume":"10","author":"Anderson","year":"2006","journal-title":"Blood"},{"key":"52","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-05-2501","article-title":"MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growthand","volume":"1","author":"Schenkein","year":"2006","journal-title":"Clin Cancer Res"},{"key":"53","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1158\/1535-7163.MCT-09-0763","article-title":"Dual inhibition of akt\/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma","volume":"9","author":"Kapoor","year":"2010","journal-title":"Mol Cancer Ther"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T16:41:22Z","timestamp":1604421682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":53,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2020,11,3]]}},"alternative-id":["27775"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27775","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]}}}